← stocks-llm Find companies like ALMS →

ALUMIS INC (ALMS)

Health Care · Immunology-focused biopharmaceutical development · NASDAQ

A clinical-stage biopharmaceutical company developing TYK2 inhibitors to replace broad immunosuppression with targeted therapies for immune-mediated diseases, with lead candidate envu advancing toward 2026 FDA submission.

View SEC filings Website Yahoo Finance Find companies like ALMS → Ask about ALMS →

What ALUMIS INC does

Alumis is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies, primarily TYK2 inhibitors, to replace broad immunosuppression in immune-mediated diseases. Its lead program, envu (envudeucitinib), is in Phase 3 development for psoriasis and Phase 2 for systemic lupus erythematosus, with an NDA submission planned for 2026. The company also develops A-005, a CNS-penetrant TYK2 inhibitor, and lonigutamab (acquired via the ACELYRIN merger), a monoclonal antibody targeting IGF-1R for thyroid eye disease.

Themes: ["TYK2 inhibitors / immune-mediated diseases","Psoriasis (plaque psoriasis)","Systemic lupus erythematosus (SLE)","Neuroinflammatory and neurodegenerative diseases","Thyroid eye disease","Targeted immunotherapy","Precision medicine approach"]

Fundamentals

Ask why ALMS looks like this →

Key risks (from latest filing)

["Clinical development risk: Envu's Phase 3 trials must demonstrate safety and efficacy sufficient for FDA approval; failure or delays in clinical trials could impair the company's ability to achieve profitability and sustain operations.","Regulatory and commercialization risk: Even if envu receives FDA approval in 2026, the company must successfully commercialize the drug and compete with existing approved therapies; failure to achieve market adoption could result in continued losses and inability to generate sustainable revenue.","Financial runway and cash burn: The company has an accumulated deficit of $994.9 million, is unprofitable with a negative net margin of -1013.23%, and has no approved products or product revenue; significant ongoing losses are expected, and the company's ability to continue operations depends on raising additional capital."]

See ALMS's biggest risks from its latest 10-Q →

Competitors & peers

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.